Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-08-29
2006-08-29
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S221000, C514S249000
Reexamination Certificate
active
07098200
ABSTRACT:
This invention provides a method of treating pain in a mammal that includes administering to a mammal in need of such treatment a pain treating effective amount of a compound of the formula (I):where R1is H, alkyl or phenylalkyl; R2is H, alkyl, alkenyl or phenylalkyl; or R1and R2taken together as Z are —CH2CH2—, —CH2(CR6)(R7)CH2— or —CH2C(R8)(R9)—C(R10)(R11)CH2—, where R6, R8and R10are, independently, H, alkyl or hydroxyl and R7, R9and R11are, independently, H or alkyl; A is alkylene or alkenylene; X is CO2R3, P(O)(OR4)(OR5), 3,5-dioxo-1,2,4-oxadiazolidin-2-yl or 5-tetrazolyl in which R3, R4and R5are, independently, H or alkyl, or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions for treating pain containing a pain treating effective amount of the compound of formula (I).
REFERENCES:
patent: 5124319 (1992-06-01), Baudy et al.
patent: 5168103 (1992-12-01), Kinney et al.
patent: 5240946 (1993-08-01), Kinney et al.
patent: 5990307 (1999-11-01), Asselin et al.
patent: 6011168 (2000-01-01), Asselin et al.
patent: 6451848 (2002-09-01), Behl et al.
patent: 2004/0082543 (2004-04-01), Cheung
patent: 0 496 561 (1992-07-01), None
patent: 0 778 023 (1997-06-01), None
patent: 0 994 107 (2000-04-01), None
patent: WO 98/15542 (1998-04-01), None
patent: WO 99/06417 (1999-02-01), None
patent: WO 99/64041 (1999-12-01), None
patent: WO 03/065982 (2003-08-01), None
patent: WO 2004/039371 (2004-05-01), None
Radanov et al, “Symptomatic approach to posttraumatic headache and its possible implications for treatment” European Spine Journal, vol. 10, pp. 403-407 (Jun. 16, 2001).
Gilron et al, “A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias” Neurology, vol. 55, pp. 964-971 (Oct. 2000).
Harrison's Principals of Internal Medicine, 13thEd., Edited by Isselbacher et al, pp. 2320-2328, © 1994 McGraw-Hill, Inc.
Bullock, “Opportunities for Neuroprotective Drugs in Clinical Management of Head Injury” The Journal of Emergency Medicine, vol. 11, pp. 23-30 (1993).
Karlsten et al., Drug & Aging, 11(5), 398-412 (1997).
Hao et al., Pain, 66, 279-285 (1996).
Chaplan et al., Pharmacology & Experimental Therapeutics, 280(2), 829-838 (1997).
Suzuki et al., Pain, 91, 101-109 (2001).
Bennett, Journal of Pain & Symptom Management, 19(1 Suppl.), S2-S6 (2000).
Sang, Journal of Pain & Symptom Management, 19 (1 Suppl.), S21-S25 (2000).
Pal et al., Burns, 23(5), 404-412 (1997).
Rogawski et al., Trends in Pharmaceutical Sciences, 14, 325-331 (1993).
Nicholson et al., Behavioural Pharmacology, 9, 231-243 (1998).
Mori et al., Behavioural Brain Research, 119, 33-40 (2001).
Baron et al., Psychopharmacology, 118, 42-51 (1995).
France et al., Journal of Pharmacology & Experimental Therapeutics, 257(2), 727-734 (1991).
France et al., European Journal of Pharmacology, 159, 133-139 (1989).
Olney et al., Science, 254, 1515-1518 (1991).
Fix et al., Experimental Neurology, 123, 204-215 (1998).
Bradford et al., Stroke & Cerebral Circulation, Abstract (1998).
Mosconi et al., Pain, 64, 37-57 (1996).
Millan et al., Neuroscience Letters, 178, 139-143 (1994).
Brandt et al., Pharmacology & Experimental Therapeutics, 296(3), 939-946 (2001).
Kinney et al., J. Med. Chem., 41, 236-246 (1998).
Mcroberts et al., Gastroenterology, 120(7), 1737-1748 (2001).
Olivar et al., Pain, 79, 67-73 (1999).
Rygh et al., Pain, 93, 15-21 (2001).
Tang et al., Nature, 401, 63-69 (1999).
Wei et al., Nature, 4(2), 164-169 (2001).
Chaplan, S.R., Journal of Neuroscience Methods, 53, 55-63 (1994).
Bennett, Gary et al., Pain, 33, 87-107 (1988).
Hewitt, David, The Clinical Journal of Pain, 16, S73-S79 (2000).
Woolf, et al., Pain, 44, 293-299 (1991).
Olney, et al., Science, 244, 1360-1362 (1989).
Abrahams et al., Emerging Drugs, 5(4), 385-413 (2000).
Herrling, P.L., Academic Press, Chapter 1, 1-6 (1997).
B.M. Swahn et al., Bioorganic & Medicinal Chemistry Letters, 6(14), 1635-1640 (1996).
Baudy et al., J. Med. Chem. 36, 331-342 (1993).
Kristensen, et al., Database Biosis, Biosciences Information Service, Abstract XP002228851.
Baudy et al., J. Med. Chem. 44, 1516-1529 (2001).
Childers et al., Drugs of the Future, 27(7), 633-638 (2002).
Kristensen, et al., Pain, 51, 249-253 (1992).
Abou-Gharbia, Abstract Paper, Am. Chem. Soc., 221stMEDI 202 (2001).
F. Menniti et al., European Journal of Pharmacology, 331, 117-126 (1997).
B. Chizh et al., TRENDS in Pharmacological Sciences, 22(12), 636-642 (2001).
S. Boyce et al., Neuropharmacology, 38, 611-623 (1999).
V. Mutel et al., Journal of Neurochemistry, 70, 2147-2155 (1998).
A. Hussain, Advanced Drug Delivery Reviews, 29, 39-49 (1998).
C. Parsons, European Journal of Pharmacology, 429, 71-78 (2001).
Sun, Lucy et al., The Journal of Pharmacology & Experimental Therapeutics, 310(2), 563-570 (2004).
Marion, Donald W. et al., The New England Journal of Medicine, 336(8), 540-546 (1997).
Rundek, Tanja et al., Acta Clin. Croat 41, 45-49 (2002).
Brandt, Michael et al., Abstract, NMDA antagonist for the treatment of diabetic neuropathy, Presented at the SMI Pain Conference in London, Jun. 9, 2004.
Brandt, Michael et al., Antiallodynic and antihyperalgesic effects of the NMDA receptor antagonist perzinfotel (EAA-090) in neuropathic pain models, Presented at Advancing Preclinical and Clinical Applications of Pain Therapeutics in San Diego, CA, Oct. 28-29 2004.
Rogers, Kathryn et al., Effects of the NMDA receptor antagonist perzinfotel (EAA-090) on chemically- induced thermal hypersensitivity, Presented at Advancing Preclinical and Clinical Applications of Pain Therapeutics in San Diego, CA, Oct. 28-29 2004.
Brandt, Michael, Efficacy of Novel NMDA Receptor Antagonists, Presented at Advancing Preclinical and Clinical Applications of Pain Therapeutics in San Diego, CA, Oct. 28-29 2004.
Wiesenfeld-Hallin, Z., “Combined Opioid-NMDA Antagonist Therapies,”Drugs, 1998, 55(1), 1-4.
Yamamoto, T., “N-methyl-D-aspartate (NMDA) receptor and pain,”Masui, Nov. 1996, 45(11), 1312-1318 [English abstract only].
Brandt Michael Richard
Moyer John Allen
Zaleska Margaret Maria
Tucker Zachary C.
Wilson James O.
Woodcock & Washburn LLP
Wyeth
LandOfFree
[[2-(Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with [[2-(Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and [[2-(Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3708594